Burlulipase
- Generic Name
- Burlulipase
- Drug Type
- Biotech
- CAS Number
- 1261982-91-5
- Unique Ingredient Identifier
- 9OI3G3SC9E
- Background
Burlulipase has been used in trials studying the treatment of Lung Diseases, Cystic Fibrosis, Pancreatic Insufficiency, Digestive System Diseases, and Respiratory Tract Diseases.
Efficacy and Tolerability of NM-BL in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
Phase 1
Completed
- Conditions
- Pancreatic InsufficiencyCystic FibrosisLung DiseasesRespiratory Tract DiseasesDigestive System Diseases
- Interventions
- Drug: Placebo (Caramel in sterile water)
- First Posted Date
- 2012-10-19
- Last Posted Date
- 2016-06-07
- Lead Sponsor
- Nordmark Arzneimittel GmbH & Co. KG
- Target Recruit Count
- 35
- Registration Number
- NCT01710644
- Locations
- 🇺🇸
Nemours Children's Clinic, Pensacola, Florida, United States
🇺🇸The University of Iowa, Iowa City, Iowa, United States
🇺🇸The Children's Medical Center of Dayton, Dayton, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath